Skip to content
HomeLatest news

Latest news

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.

6 ways Johnson & Johnson is using AI to help advance healthcare

Artificial intelligence is revolutionizing healthcare—from improving surgical training and procedures to equipping healthcare providers with insights and personalizing care for patients around the world. See how the company is harnessing its extraordinary power.

More from Johnson & Johnson

What you need to know about Johnson & Johnson’s 2024 third quarter earnings

Check out this infographic breakdown of the company’s third quarter performance, with highlights from its Innovative Medicine and MedTech businesses.

What is a rheumatic disease?

More than 200 conditions are classified as rheumatic diseases, including rheumatoid arthritis, lupus and Sjögren’s disease. They tend to affect the joints and connective tissues, causing pain and swelling and impacting quality of life. Here’s what a doctor wants you to know about the different types, symptoms and risk factors—and how Johnson & Johnson is innovating new treatments.

Meet the medical engineer behind the innovative heart pump that revolutionized cardiac health

Drawing on his fascination with airplane technology, Thorsten Siess, Ph.D., came up with an idea that became the Impella heart pump. Now, 25 years since it entered the market, this groundbreaking device has helped more than 330,000 patients recover from heart injuries.

What’s the difference between a heart attack and cardiac arrest?

Both are life-threatening heart-health emergencies, but they are two distinct conditions with different causes and treatment. Here’s what a cardiologist wants you to know.

What you need to know about Johnson & Johnson’s 2023 transparency report

The annual report has just been released—here are key takeaways that showcase the company’s commitment to creating a more sustainable, equitable and innovative healthcare system.

How Johnson & Johnson is fighting counterfeit medical products

Fake medication and compromised devices are part of a global market that poses a significant threat to the health of patients. Here’s how the company’s Global Brand Protection team helps keep people safe.
Bottles of counterfeit drugs
Photo courtesy of GBP LATAM team

Press releases

Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor

Following recent U.S. FDA approval of TREMFYA® for adults with moderately to severely active ulcerative colitis (UC), this submission underscores its potential to be the only IL-23 inhibitor that offers choice of subcutaneous or intravenous induction in UC Submission is supported by the Phase 3 ASTRO study, which achieved the primary endpoint of clinical remission at Week 12 and met all secondary endpoints in adults with moderately to severely active UC

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting

More than 90 presentations of clinical trial and real-world data highlight potentially practice-changing evidence and commitment to pioneer the next wave of therapies for patients with hematologic malignancies

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results

Icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, met its co-primary endpoints in patients with moderate to severe plaque psoriasis 74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24 Comprehensive results are being prepared for presentation at upcoming medical congresses

CHMP recommends RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer

The amivantamab plus lazertinib combination regimen offers potential to provide new standard of care as first-line option for adult patients with advanced NSCLC with EGFR ex19del or L858R substitution mutations1 In the Phase 3 MARIPOSA study, amivantamab plus lazertinib significantly reduced risk of disease progression or death by 30 percent versus osimertinib monotherapy1

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren’s disease study

Adults with moderately-to-severely active Sjögren’s disease who received investigational FcRn blocker nipocalimab had improvements in disease activity scores at 24 weeks with accompanying significant reductions in IgG and autoantibody levels Nipocalimab was granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren’s disease based on results from the Phase 2 DAHLIAS study

Johnson & Johnson MedTech Announces Strategic Agreement with Responsive Arthroscopy to Expand Sports Soft Tissue Solutions

New collaboration to strengthen and deliver advanced soft tissue repair solutions for shoulder, foot and ankle procedures

More from Johnson & Johnson

Diversity in the OR: 3 barrier-breaking female surgeons share their stories

Only one in 10 orthopedic surgeons in the U.S. are women. Learn how Johnson & Johnson is working to change that stat.

What are cataracts?

If you can’t read a screen without jacking up the brightness level or if night driving leaves you seeing fuzzy halos around traffic lights, you may among the 20 million U.S. adults who develops a cataract—the most common cause of vision loss worldwide. Luckily a simple surgical procedure can have you viewing the world in crisp, bright color again. Here’s what to know about cataract symptoms and removal.

Meet two brothers who are revolutionizing the way scientists develop treatments for cancer

Justin and Colin Farlow share how their next-generation cell and gene therapies are helping Johnson & Johnson in its quest to get in front of cancer.